2020 MCRN共识指南:多发性骨髓瘤及相关疾病的诊断

2020-02-04 国外血液科相关专家小组 Clin Lymphoma Myeloma Leuk. 2020 Feb 4.

多发性骨髓瘤(MM)是骨髓中浆细胞恶性增殖导致单克隆免疫球蛋白及其片段(M蛋白)分泌过多,引起相关器官或组织损伤的一种血液系统恶性肿瘤。本文主要针对多发性骨髓瘤及相关疾病的诊断提出指导建议,重点关注广

中文标题:

2020 MCRN共识指南:多发性骨髓瘤及相关疾病的诊断

英文标题:

Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium.

发布日期:

2020-02-04

简要介绍:

多发性骨髓瘤(MM)是骨髓中浆细胞恶性增殖导致单克隆免疫球蛋白及其片段(M蛋白)分泌过多,引起相关器官或组织损伤的一种血液系统恶性肿瘤。本文主要针对多发性骨髓瘤及相关疾病的诊断提出指导建议,重点关注广泛可用的检测方法。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=7fafd1c001891385, title=2020 MCRN共识指南:多发性骨髓瘤及相关疾病的诊断, enTitle=Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium., guiderFrom=Clin Lymphoma Myeloma Leuk. 2020 Feb 4., authorId=0, author=, summary=多发性骨髓瘤(MM)是骨髓中浆细胞恶性增殖导致单克隆免疫球蛋白及其片段(M蛋白)分泌过多,引起相关器官或组织损伤的一种血液系统恶性肿瘤。本文主要针对多发性骨髓瘤及相关疾病的诊断提出指导建议,重点关注广, cover=https://img.medsci.cn/2020414/1586864427096_2020535.jpg, journalId=0, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Tue Feb 04 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>多发性骨髓瘤(MM)是骨髓中浆细胞恶性增殖导致单克隆免疫球蛋白及其片段(M蛋白)分泌过多,引起相关器官或组织损伤的一种血液系统恶性肿瘤。本文主要针对多发性骨髓瘤及相关疾病的诊断提出指导建议,重点关注广泛可用的检测方法。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=321, tagName=多发性骨髓瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=321, guiderKeyword=多发性骨髓瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2501, appHits=121, showAppHits=28, pcHits=771, showPcHits=2389, likes=1, shares=7, comments=6, approvalStatus=1, publishedTime=Tue Apr 14 19:53:13 CST 2020, publishedTimeString=2020-02-04, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Apr 14 19:40:31 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 07:04:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1056559, encodeId=dc6610565595f, content=有翻译版本吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:35:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000242, encodeId=086d1000242d3, content=受教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fec5421002, createdName=ms6000000881091992, createdTime=Fri Jul 16 22:29:14 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902333, encodeId=f87e902333d8, content=知识更新了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:05:32 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899775, encodeId=fd4c899e75a0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e53c1579965, createdName=vini_wb, createdTime=Tue Nov 17 08:53:56 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2021-09-30 13f0c37dm61暂无昵称

    有翻译版本吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1056559, encodeId=dc6610565595f, content=有翻译版本吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:35:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000242, encodeId=086d1000242d3, content=受教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fec5421002, createdName=ms6000000881091992, createdTime=Fri Jul 16 22:29:14 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902333, encodeId=f87e902333d8, content=知识更新了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:05:32 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899775, encodeId=fd4c899e75a0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e53c1579965, createdName=vini_wb, createdTime=Tue Nov 17 08:53:56 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2021-07-16 ms6000000881091992

    受教

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1056559, encodeId=dc6610565595f, content=有翻译版本吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:35:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000242, encodeId=086d1000242d3, content=受教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fec5421002, createdName=ms6000000881091992, createdTime=Fri Jul 16 22:29:14 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902333, encodeId=f87e902333d8, content=知识更新了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:05:32 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899775, encodeId=fd4c899e75a0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e53c1579965, createdName=vini_wb, createdTime=Tue Nov 17 08:53:56 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2020-11-26 慕尔

    知识更新了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1056559, encodeId=dc6610565595f, content=有翻译版本吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:35:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000242, encodeId=086d1000242d3, content=受教, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fec5421002, createdName=ms6000000881091992, createdTime=Fri Jul 16 22:29:14 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902333, encodeId=f87e902333d8, content=知识更新了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:05:32 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899775, encodeId=fd4c899e75a0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e53c1579965, createdName=vini_wb, createdTime=Tue Nov 17 08:53:56 CST 2020, time=2020-11-17, status=1, ipAttribution=)]
    2020-11-17 vini_wb

    好好学习

    0

拓展阅读

2015 IMWG 多发性骨髓瘤患者管理中MRI应用的共识声明

国际骨髓瘤工作组(IMWG,International Myeloma Working Group) · 2015-01-20

2015 ASBMT指南:造血干细胞移植治疗多发性骨髓瘤

美国血液与骨髓移植学会(ASBMT,American Society for Blood and Marrow Transplantation) · 2015-03-10

中国多发性骨髓瘤诊治指南(2015年修订)

中国医师协会血液科医师分会 · 2015-12-01

多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)

中国医师协会血液科医师分会 · 2015-09-08

2016 新加坡骨髓瘤研究组共识指南:多发性骨髓瘤患者的管理

新加坡骨髓瘤研究组(Singapore Myeloma Study Group) · 2016-09-09

2016 SIN立场声明:体外轻链去除技术治疗多发性骨髓瘤导致的急性肾损伤

意大利肾病学会(SIN,Italian Society of Nephrology) · 2016-10-18